Loading clinical trials...
Loading clinical trials...
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Conditions
Interventions
dabrafenib
trametinib
Locations
28
United States
Honor Health Research Institute
Scottsdale, Arizona, United States
Honor Health Research Institute
Scottsdale, Arizona, United States
National Institute Of Health
Bethesda, Maryland, United States
James Cancer Hospital and Solove Research Institute Ohio State
Columbus, Ohio, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Start Date
December 28, 2017
Primary Completion Date
December 28, 2032
Completion Date
December 28, 2032
Last Updated
April 20, 2026
NCT05671510
NCT07489378
NCT07181681
NCT06257264
NCT07204340
NCT05969860
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions